Abstract
Purpose
SU5416 is a small, lipophilic synthetic molecule that selectively inhibits the tyrosine kinase activity of the VEGF receptor Flk-1/KDR. The role of this agent in brain tumors is currently being investigated. Pharmacokinetic studies of SU5416 have been performed in humans; however, there have been no studies of its penetration in the cerebrospinal fluid (CSF). We studied the pharmacokinetics of SU5416 in plasma and CSF after intravenous (i.v.) administration using a nonhuman primate model that is highly predictive of the CSF penetration in humans.
Experimental design
SU5416 (85 mg/m2, about 3.8 mg/kg) was administered i.v. over 20 min to four nonhuman primates. Serial plasma and CSF samples were obtained prior to, during, and after completion of the infusion for determination of SU5416 concentrations. SU5416 was measured in plasma and CSF using high-performance liquid chromatography (HPLC). Concentration-versus-time data were modeled using model-independent and model-dependent methods.
Results
Peak plasma concentrations ranged from 6.3 to 14.5 μM and the mean plasma AUC was 620±180 μM·min. Disappearance of SU5416 from the plasma was best described by a one-compartment model with a half-life of 39±2.9 min. The volume of distribution was 36±11 l/m2 and the clearance was 0.62±0.2 l/min per m2. SU4516 was not quantifiable in the CSF.
Conclusions
There is minimal penetration of SU5416 into the CSF after i.v. administration. The very low CNS exposure to SU5416 after i.v. dosing suggests that this agent is not optimal for the treatment of leptomeningeal tumors.
Similar content being viewed by others
References
Cropp G, Rosen L, Mulay M, Langecker P, Hannah A (1999) Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose escalating trial in patients with advanced malignancies (abstract 619). Proc Am Soc Clin Oncol 18:161a
Donelli MG, Zucchetti M, D’Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251–260
Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5 [Suppl 1]:11
Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99
Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJF, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657
McCully C, Balis F, Bacher J, Phillips J, Poplack D (1990) Rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40:520
McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5 [Suppl 1]:3
Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM (2000) Development of SU5416, a selective small molecule inhibitor of the VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent. Anticancer Drug Des 13:29
National Institutes of Health (1988) Guide for the care and use of laboratory animals. Department of Health, Education and Welfare (DHEW) publication (NIH) 85
Poplack DG, Bleyer WA, Wood JH, Kostolich M, Savitch JL, Ommaya AK (1977) A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res 37:1982
Rosen L, Mulay M, Mayers A, Kabbinavar F, Rosen P, Cropp G, Hannah A (1999) Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies (abstract 618). Proc Am Soc Clin Oncol 18:161a
Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412
Shargel L, Yu ABC (eds) (1999) Applied biopharmaceutics and pharmacokinetics. McGraw-Hill, New York
Sukbunterng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L (2001) Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 53:1629
Acknowledgement
This work was supported in part by UOI HD37242 and the Glaser Pediatric Research Network.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Renbarger, J., Aleksic, A., McGuffey, L. et al. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol 53, 39–42 (2004). https://doi.org/10.1007/s00280-003-0683-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-003-0683-z